ArticleFrontiers in microbiology2025
Bloodstream infections epidemiology and clinical outcomes after 1 year post allogeneic hematogenous stem cell transplantation.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bloodstream infections (BSIs) are a serious threat for patients undergoing allogenic hematopoietic stem cell transplants (a-HSCT). MDR colonization is highly prevalent among a-HSCT patients, due to drug-induced intestinal dysbiosis. Primary outcome of the study was to assess the epidemiology and risk factors for BSIs in the 1st year after a-HSCT. Secondary endpoints were to examine the prevalence of MDR bacterial colonization and factors affecting 1-year post-transplant overall survival (OS). Methods: In this single-center observational cohort study, all consecutive adult patients undergoing a-HSCT for hematological malignancies between 2012 and 2021 were retrospectively enrolled at the Stem Cell Transplant Center, AOU Città della Salute e della Scienza, Turin (Italy). Cumulative Incidence and risk factors for BSIs were analyzed by Gray and Fine-Gray tests, respectively. OS was evaluated with Kaplan-Meier, while the influence of covariates on OS with Cox regression analysis. Results: Two hundred and seventy nine patients were enrolled in the study, 43% of which developed BSI within the 1st-year post-transplant. The median onset of BSIs was 10 days after a-HSCT and Gram-negative bacteria were the most common causative agents (58.3%). 20.8% of patients had a positive rectal swab (RS) for MDR bacteria, with extended-spectrum β-lactamases (ESBLs)-producing Conclusions: BSIs are common complications in a-HSCT, with evidence suggesting a negative impact on OS. Although MDR colonization is not independently linked to increased mortality in a-HSCT, it appears to be associated with an elevated risk of subsequent BSI development. These findings underscore the potential value of pre-transplant surveillance, contact precautions, and early targeted antimicrobial therapy in colonized patients to help mitigate infection-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.